Research Papers

25 of 83 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Polypharmacy and potential drug-drug interactions among Greenland's care home residents.
Albertsen N; Sommer TG; Olsen TM; Prischl A; Kallerup H; Andersen S.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database.
Yoshida Y; Sasaoka S; Tanaka M; Matsumoto K; Inoue M; Satake R; Shimada K; Mukai R; Suzuki T; Iwata M; Goto F; Mori T; Mori K; Yoshimura T; Nakamura M.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Ten-year trends in adverse drug reaction-related hospitalizations among people with dementia.
Zaidi AS; Peterson GM; Bereznicki LRE; Curtain CM; Salahudeen MS.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Self-medication and the 'infodemic' during mandatory preventive isolation due to the COVID-19 pandemic.
Gaviria-Mendoza A; Mejía-Mazo DA; Duarte-Blandón C; Castrillón-Spitia JD; Machado-Duque ME; Valladales-Restrepo LF; Machado-Alba JE.
Ther Adv Drug Saf (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Use of an electronic medication management support system in patients with polypharmacy in general practice: study prot…
Brünn R; Lemke D; Chapidi K; Köberlein-Neu J; Piotrowski A; Söling S; Greiner W; Kellermann-Mühlhoff P; Timmesfeld N; van den Akker M; Muth C; AdAM study group.
Ther Adv Drug Saf (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Prospective cohort study of nonspecific deprescribing in older medical inpatients being discharged to a nursing home.
Russell P; Hewage U; McDonald C; Thompson C; Woodman R; A Mangoni A.
Ther Adv Drug Saf (Unknown)
Published: 2021
3/6 Transparent
Registered Funding Declared
Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a syste…
Shrestha S; Poudel A; Cardona M; Steadman KJ; Nissen LM.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observati…
Santenna C; Vidyasagar K; Amarneni KC; Ghanta SN; Sadasivam B; Pathan S; Padmavathi R.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approa…
Thomas L; Birangal SR; Ray R; Sekhar Miraj S; Munisamy M; Varma M; S V CS; Banerjee M; Shenoy GG; Rao M.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Patient harm from cardiovascular medications.
Paradissis C; Cottrell N; Coombes I; Scott I; Wang W; Barras M.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Inappropriate medications and physical function: a systematic review.
Manias E; Kabir MZ; Maier AB.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analys…
Wang LT; Lin WT; Lai CC; Wang YH; Chen CH; Chang YT; Chen CH; Wang CY.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Tramadol-induced hiccups: a case-noncase study in the European pharmacovigilance database.
García M; Lertxundi U; Aguirre C.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.
Thouvenin L; Olivier T; Banna G; Addeo A; Friedlaender A.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review.
Yuet WC; Ebert D; Jann M.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmacies.
Berger FA; van der Sijs H; van Gelder T; van den Bemt PMLA.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19.
Myint PK; Carter B; Barlow-Pay F; Short R; Einarsson AG; Bruce E; McCarthy K; Verduri A; Collins J; Hesford J; Rickard F; Mitchell E; Holloway M; McGovern A; Vilches-Moraga A; Braude P; Pearce L; Stechman M; Price A; Quinn TJ; Clini E; Moug S; Hewitt J.
Ther Adv Drug Saf (Unknown)
Published: 2021
3/6 Transparent
Registered Funding Declared
Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated w…
Sharma JB; Krishnamurthy MN; Awase A; Joshi A; Patil V; Noronha V; Prabhash K; Gota V.
Ther Adv Drug Saf (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic revie…
Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM.
Ther Adv Drug Saf (Unknown)
Published: 2021
4/6 Transparent
Registered Funding Declared
The art and science of drug titration.
Caffrey AR; Borrelli EP.
Ther Adv Drug Saf (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Antiretroviral therapy and liver disorders in the OPERA<sup>®</sup> cohort.
Wohlfeiler M; Mounzer K; Brunet L; Fusco J; Vannappagari V; Curtis L; Payvandi N; Aboud M; Hsu R; Lackey P; Fusco G.
Ther Adv Drug Saf (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Effects of stratified medication review in high-risk patients at admission to hospital: a randomised controlled trial.
Bonnerup DK; Lisby M; Sædder EA; Brock B; Truelshøj T; Sørensen CA; Pedersen AG; Nielsen LP.
Ther Adv Drug Saf (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations.
Biswas PS; Sen D.
Ther Adv Drug Saf (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
QT interval prolongation and <i>Torsades de Pointes</i> with donepezil, rivastigmine and galantamine.
Malone K; Hancox JC.
Ther Adv Drug Saf (Unknown)
Published: 2020
2/6 Transparent
Funding Declared